|
|
|
|
||
Fortune magazine 2016 prediction re AlzheimerDecember 1, 2015 issue of Fortrune magazine in their "The 2016 Fortune Crystal Ball" feature made the following prediction: WE'LL GET GOOD NEWS IN THE ALZHEIMER'S FIGHT "Existing Alzheimer's therapies treat only the symptoms of the memory- robbing condition, not the disease itself. And between 2002 and 2012, a staggering 99.6% of drugs in development failed. But 2016 should deliver a breakthrough: By year's end, Eli Lilly's solanezumab--a drug 15 years in the making--will pass muster in clinical tests and be well on its way to FDA approval as a therapy for mild Alzheimer's." It was only a few years ago(2005-2007) that Elan was considered the leader in Alzheimer's research and development, now just a fading footnote in Alzheimer's annals. In the same issue, Fortune revealed their choice of the Top 20 People in Business. In number 10 spot is George Scangos, CEO, Biogen. In the leadership area Elan drew the short straw, with an Irish BoD dominated by brokers, bankers, and accountants picking a Wall Street broker to run a business he knew nothing about, and had rich spending habits. It didn't take Martin and the Irish BoD that long to drive Elan, a very promising biotech in 2006-2007, into the ground. But at least the Alzheimer's patients will benefit from the groundbreaking research and development of Elan scientists. |
return to message board, top of board |